Pimicotinib, sold under the brand name Pimjetmi, is an anti-cancer medication used for the treatment of tenosynovial giant cell tumor. It is an oral, highly potent and selective small molecule blocker of the colony-stimulating factor 1 receptor discovered by Abbisko Therapeutics.
Medical uses Pimicotinib is indicated for the treatment of adults with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
History In December 2023, Abbisko Therapeutics entered into a licensing agreement for pimicotinib in all indications for China rights with Merck KGaA. Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib. (2023) https://www.merckgroup.com/en/news/abbisko-pimicotinib-agreement-04-12-2023.html Merck KGaA buys into Abbisko's late-stage joint tumor med for $70M upfront. Fierce Biotech. (2023) https://www.fiercebiotech.com/biotech/merck-kgaa-buys-abbiskos-late-stage-joint-tumor-med-70m-upfront
In April 2023, a global phase III, randomized, double-blind, placebo-controlled, multi-center clinical trial designed to evaluate the safety and efficacy of pimicotinib in people with tenosynovial giant cell tumor was started (NCT05804045).
Following with pimicotinib for tenosynovial giant cell tumor treatment in phase III, pimicotinib has also entered into a phase II trial in June 2023, for Graft-versus-host disease treatment in China.A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) U. S. National Institutes of Health, National Cancer Institute. https://classic.clinicaltrials.gov/ct2/show/NCT06186804
The US Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of NMPA granted pimicotinib breakthrough therapy designation for the treatment of people with tenosynovial giant cell tumor that are not amenable to surgery in January 2023 and July 2022, respectively.
References
Further reading
External links